Global pharmaceutical major Lupin Limited has announced a strategic license and supply agreement with SteinCares, a prominent specialty healthcare company in Latin America, for the commercialization of its biosimilar Ranibizumab across the region—excluding Mexico and Argentina.
Under the agreement, SteinCares will be responsible for regulatory filings, product registration, and marketing of Ranibizumab in Latin American markets, while Lupin will oversee the manufacturing of the drug.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is indicated for several serious retinal conditions, including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularization (mCNV).
Commenting on the partnership, Dr. Cyrus Karkaria, President – Biotechnology at Lupin, said, “This collaboration with SteinCares highlights our commitment to delivering cutting-edge, affordable therapies to patients in Latin America. Our goal is to expand access to advanced retinal care solutions that enhance patient outcomes and quality of life.”
Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Partnering with Lupin further strengthens our growing biosimilar portfolio and cements our leadership in the LATAM region. By introducing high-quality products sourced from regulated markets, we’ve consistently delivered cost-effective solutions to healthcare systems throughout Latin America, leveraging decades of market expertise.”